Amikacin (AkicinTM) is indicated in the short-term treatment of serious infections due to susceptible strains of Gram-negative bacteria. Amikacin is effective in bacterial septicemia (including neonatal sepsis); in serious infections of the respiratory tract, bones and joints, central nervous system (including meningitis) and skin and soft tissue; intra-abdominal infections (including peritonitis); and in burns and postoperative infections (including post vascular surgery). Clinical studies have shown that Amikacin is also effective in serious complicated and recurrent urinary tract infections due to those organisms.
Dosage & Administration:
Adults and children: 15 mg/kg/day in two equally divided doses (equivalent to 500 mg b.i.d. in adults); use of the 100 mg/2ml strength is recommended for children for the accurate measurement of the appropriate dose. Neonates and premature infants: An initial loading dose of 10 mg/kg/day followed by 15 mg/kg/day in two equally divided doses.
Elderly: Amikacin is excreted by the renal route. Renal function should be assessed whenever possible and dosage adjusted as described under impaired renal function. Life-threatening infections and/or those caused by Pseudomonas bacteria: The adult dose may be increased to 500 mg every eight hours but should neither exceed 1.5 g/day nor be administered for a period longer than 10 days. A maximum total adult dose of 15g should not be exceeded. Urinary tract infections: (other than pseudomonal infections): 7.5 mg/kg/day in two equally divided doses (equivalent to 250 mg b.i.d. in adults). Impaired renal function: In patients with impaired renal function, the daily dose should be reduced and/or the intervals between doses increased to avoid accumulation of the drug.
AkicinTM 100 IM/IV Injection: Each box contains 10 ampoules in Alu-PVC blister pack.
AkicinTM 500 IM/IV Injection: Each box contains 10 ampoules in Alu-PVC blister pack.